Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Maximiliano Van Kooten"'
Autor:
Yanfang Liu, Hirotsugu Uemura, Dingwei Ye, Ji Y. Lee, Edmund Chiong, Yeong-S. Pu, Azad H.A. Razack, Choosak Pripatnanont, Sudhir Rawal, Grace K.M. Low, Hong Qiu, Weng H. Chow, Maximiliano Van Kooten Losio
Publikováno v:
Prostate International, Vol 7, Iss 3, Pp 108-113 (2019)
Background: The incidence of prostate cancer (PC) in Asian countries is increasing for reasons that are not clear. Data describing how PC is diagnosed and treated are fragmented across Asia, with marked intercountry and intracountry differences in ou
Externí odkaz:
https://doaj.org/article/64333ceb7def4e939241dc64f9574ffe
Autor:
Toni K. Choueiri, Thomas Powles, Laurence Albiges, Mauricio Burotto, Cezary Szczylik, Bogdan Zurawski, Eduardo Yanez Ruiz, Marco Maruzzo, Alberto Suarez Zaizar, Luis E. Fein, Fabio A. Schutz, Daniel Y.C. Heng, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Cristina Suarez, Robert J. Motzer
Publikováno v:
New England Journal of Medicine. 388:1767-1778
Autor:
Thomas Powles, Robert J. Motzer, Laurence Albiges, Cristina Suárez, Fabio A. B. Schutz, Daniel Yick Chin Heng, Christine Chevreau, Ravindran Kanesvaran, Howard Gurney, Fong Wang, Fabio Mataveli, Yu-Lin Chang, Maximiliano van Kooten Losio, Toni K. Choueiri
Publikováno v:
Journal of Clinical Oncology. 41:605-605
605 Background: In COSMIC-313 (NCT03937219), C+N+I significantly improved progression-free survival (PFS) compared with N+I in first-line aRCC of IMDC intermediate or poor risk (Choueiri ESMO 2022). Here, outcomes are analyzed by IMDC risk group. Met
Autor:
Choung Soo Kim, Sudhir Rawal, Hao Zeng, Weiping Liu, Yeong-Shiau Pu, Marxengel Asinas-Tan, Byung Ha Chung, Edmund Chiong, Chikara Ohyama, Noor Ashani Md Yusoff, Dingwei Ye, Yuh-Shyan Tsai, Azad Hassan Abdul Razack, Bannakij Lojanapiwat, Hirotsugu Uemura, Sunai Leewansangtong, Y. Liu, Ravindran Kanesvaran, Maximiliano van Kooten Losio
Publikováno v:
Bju International
Objectives To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real‐world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods We establis
Autor:
Hong Qiu, Choosak Pripatnanont, Maximiliano van Kooten Losio, Y. Liu, Weng H. Chow, Azad Hassan Abdul Razack, Grace K.M. Low, Edmund Chiong, Ji Y. Lee, Hirotsugu Uemura, Sudhir Rawal, Yeong S. Pu, Dingwei Ye
Publikováno v:
Prostate International, Vol 7, Iss 3, Pp 108-113 (2019)
Prostate International
Prostate International
Background: The incidence of prostate cancer (PC) in Asian countries is increasing for reasons that are not clear. Data describing how PC is diagnosed and treated are fragmented across Asia, with marked intercountry and intracountry differences in ou
Autor:
Philip Campbell, Lugui Qiu, Jian Hou, Noemi Horvath, Michael Eisbacher, Sarah Siggins, Maximiliano van Kooten Losio, Anna Kalff, Melita Kenealy, Andrew Spencer, Douglas E. Joshua, Je-Jung Lee, H. Miles Prince, Anil Londhe, Tiffany Khong
Publikováno v:
Leukemia & Lymphoma. 60:2122-2133
Efficacy and safety of bortezomib-based consolidation following ASCT were investigated in newly diagnosed multiple myeloma patients from Australia, Korea, and China. Patients received three cycles of bortezomib-cyclophosphamide-dexamethasone inductio
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Vinod Ganju, D.H. Lee, Jie Wang, Luis Manuel Martínez-Barrera, José Rodrigues-Pereira, Manuel Magallanes, Mauro Orlando, Helen Barraclough, Joo Hang Kim, Maximiliano Van Kooten
Publikováno v:
Journal of Thoracic Oncology. 6(11):1907-1914
This study compared survival without toxicity in patients with advanced, nonsquamous non-small cell lung cancer who were treated with first-line pemetrexed/carboplatin or docetaxel/carboplatin.This multicenter, open-label, parallel-group, phase 3 tri